

Microba receives approval of two further R&D Tax Incentive Advanced Overseas Findings

Microba Life Sciences Limited (ASX: MAP) ("Microba") is pleased to announce that it has received approval from AusIndustry for two separate applications for Advanced Overseas Findings for overseas research and development expenditure associated with its Inflammatory Bowel Disease (IBD) and Immuno-oncology programs. These two new Advanced Overseas Findings are in addition to the two Advanced Overseas Findings that were announced to the ASX on 22 July 2022 for eligible overseas expenditure up to \$13,400,000. The two Advanced Overseas Findings cover total overseas expenditure of an estimated \$1,210,000 and may result in additional R&D Tax Incentive cash rebates to the Company of \$526,000.

The findings cover financial years 2023, 2024 and 2025 and mean that these eligible overseas research and development expenditures related to Microba's IBD and Immuno-oncology programs, in addition to eligible Australian expenditure, will receive a 43.5% cash rebate under the Australian Federal Government's R&D Tax Incentive Program.

Microba's Chief Executive Officer, Dr. Luke Reid, said, "We sincerely appreciate this support from the Australian Government enabling us to build a world leading microbiome company from Australia. We believe that Microba's novel therapeutics can make a positive impact on Australian lives in the future, and the R&D Tax Incentive Program is supporting Microba to make this a reality."

This announcement has been authorised for release by the Chairman and Chief Executive Officer.

For further information, please contact:

Dr Luke Reid
Chief Executive Officer
E: Luke.Reid@microba.com

Simon Hinsley
Investor / Media Relations
E: simon@nwrcommunications.com.au
T: +61 401 809 653

About Microba Life Sciences Limited

Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.

For more information visit: www.microba.com

Microba encourages all current investors to go paperless by registering their details with the designated registry service provider, Automic Group.